drugset / Trial / NCT04762810

A Prospective Study of Cyclophosphamide Treatment for Idiopathic Retroperitoneal Fibrosis

NCT04762810

Phase 4 Unknown 40 enrolled Peking Union Medical College Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This prospective, interventional, controlled study is aimed to evaluate the efficacy and safety of cyclophosphamide in the treatment of idiopathic retroperitoneal fibrosis, which refers to the chronic nonspecific inflammation of retroperitoneal fascia and adipose tissue that gradually evolves into fibroproliferative disease.

Timeline

Start
2020-01-03
Primary completion
2023-02-10
Completion
2023-02-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 50 mg
Comparator Prednisolone Other / unclassified 5 mg
Comparator Prednisone Other / unclassified 5 mg

Indications

No indication recorded.